|
|
||||||||

1 Division of Infectious Diseases, Children's Hospital Research Foundation, Elland and Bethesda Avenues, Cincinnati, Ohio 45229
and2 James N. Gamble Institute of Medical Research, 2141 Auburn Avenue, Cincinnati, Ohio 45219, U.S.A.
Exposure to u.v. radiation increases the local level of prostaglandins which may play a role in u.v. radiation-induced herpes simplex virus (HSV) recurrences. We used the guinea-pig model of u.v. radiation-induced recurrent genital HSV-2 disease for examining the effects of indomethacin, a prostaglandin inhibitor, on u.v.-induced recurrences. In the first experiment, performed 100 days after HSV-2 inoculation, treatment with indomethacin for 5 days begun 24 h before u.v.-irradiation decreased the proportion of animals developing HSV disease recurrences from 11/13 (84.6%) to 2/13 (15.4%) (P < 0.001). In the second experiment, performed 135 days after HSV-2 inoculation, treatment with indomethacin for 5 days begun 24 h before u.v.-irradiation decreased the number of animals developing recurrences from 12/21 (57.1%) to 5/21 (23.8%) (P < 0.05). Five days of indomethacin treatment begun 4 h after u.v.-irradiation, however, did not reduce the percentage of animals developing disease recurrences but did decrease the mean number of days with recurrent lesions in animals that developed recurrences. Our data suggest that indomethacin may modify u.v. radiation-induced recurrent lesions by decreasing viral reactivation when given before u.v. radiation exposure or by reducing prostaglandin-induced immunosuppression when given before or after exposure. Future studies are needed for evaluating indomethacin prophylaxis for recurrent HSV disease when prolonged u.v. radiation exposure is anticipated.
Present address: Combined Departments of Pediatrics, Creighton University and the University of Nebraska, and the Department of Medical Microbiology, Creighton University College of Medicine, 601 North 30th Street, Suite 6820, Omaha, Nebraska 68131, U.S.A.
Received 9 February 1993;
accepted 10 May 1993.
This article has been cited by other articles:
![]() |
N. Sharma-Walia, H. Raghu, S. Sadagopan, R. Sivakumar, M. V. Veettil, P. P. Naranatt, M. M. Smith, and B. Chandran Cyclooxygenase 2 Induced by Kaposi's Sarcoma-Associated Herpesvirus Early during In Vitro Infection of Target Cells Plays a Role in the Maintenance of Latent Viral Gene Expression. J. Virol., July 1, 2006; 80(13): 6534 - 6552. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ray, M. E. Bisher, and L. W. Enquist Cyclooxygenase-1 and -2 Are Required for Production of Infectious Pseudorabies Virus J. Virol., December 1, 2004; 78(23): 12964 - 12974. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Symensma, D. Martinez-Guzman, Q. Jia, E. Bortz, T.-T. Wu, N. Rudra-Ganguly, S. Cole, H. Herschman, and R. Sun COX-2 Induction during Murine Gammaherpesvirus 68 Infection Leads to Enhancement of Viral Gene Expression J. Virol., December 1, 2003; 77(23): 12753 - 12763. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Mocarski Jr. Virus self-improvement through inflammation: No pain, no gain PNAS, March 19, 2002; 99(6): 3362 - 3364. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |